For the past 7 years Merck has maintained a star rating by its program for Bridion (sugammadex), remaining convinced of its big market potential and staying upbeat after three consecutive rejections at the hands of the FDA. But regulators finally relented today, giving the pharma giant a green light on its fourth try for the drug, which is used to reverse the effects of adult anesthetics.
Merck execs used their quarterly review today to confirm that the troubled drug Bridion (sugammadex) has once again been rejected at the FDA. This is the drug's third stiff arm at the agency.
Merck is in a world of hurt. The pharma giant managed to spook several analysts with the news that its osteoporosis drug odanacatib would be held back from regulators until more data could be obtained in a trial extension, raising fears that the badly needed drug may be about to jump the tracks.
Merck today says it has the late-stage data it needs to gain an approval for a new insomnia drug, one of 5 treatments the pharma giant believes it can gain an official OK on before the end of 2013....
Schering-Plough's stock fell on the surprising news that the FDA rejected Bridion (sugammadex), a treatment to reverse muscle relaxation during general anesthesia. The FDA expressed concern over
Schering-Plough says the EC has approved Bridion (sugammadex) injection, "the first and only selective relaxant binding agent and the first major pharmaceutical advance in the field of anesthesia in
The European Union approved Shering-Plough's Bridion (sugammadex) in an injection form for the purposes of reversing neuromuscular blockade during general anesthesia more rapidly. This will be the